Comments

Mereo BioPharma Group

MREONASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$3.93
-0.16-3.91%
Last update: 11:06 AM
15 minutes delayed
Mereo BioPharma Group (MREO) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Outperform
Highest Price Target1
$8.00
Lowest Price Target1
$4.00
Consensus Price Target1
$6.80

want to know what
the Bulls & Bears Say?

Mereo BioPharma Group (NASDAQ:MREO) Stock, Analyst Ratings, Price Targets, Forecasts

Mereo BioPharma Group PLC has a consensus price target of $6.8 based on the ratings of 5 analysts. The high is $8 issued by Leerink Partners on June 20, 2024. The low is $4 issued by SVB Leerink on November 10, 2022. The 3 most-recent analyst ratings were released by Leerink Partners, Baird, and Cantor Fitzgerald on June 20, 2024, June 13, 2024, and June 12, 2024, respectively. With an average price target of $7.67 between Leerink Partners, Baird, and Cantor Fitzgerald, there's an implied 95.08% upside for Mereo BioPharma Group PLC from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Mar
0
0
0
0
Apr
1
May
3
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.5
Strong Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Leerink Partners
Baird
Cantor Fitzgerald
Needham
SVB Leerink

1calculated from analyst ratings

Analyst Ratings for Mereo BioPharma Group

Buy NowGet Alert
06/20/2024Buy Now103.56%Leerink Partners
Joseph Schwartz
$6 → $8MaintainsOutperformGet Alert
06/13/2024Buy Now103.56%Baird
Jack Allen
→ $8Initiates → OutperformGet Alert
06/12/2024Buy Now78.12%Cantor Fitzgerald
Kristen Kluska
$7 → $7ReiteratesOverweight → OverweightGet Alert
06/12/2024Buy Now78.12%Needham
Gil Blum
$6 → $7MaintainsBuyGet Alert
05/16/2024Buy Now78.12%Cantor Fitzgerald
Kristen Kluska
 → $7ReiteratesOverweight → OverweightGet Alert
05/16/2024Buy Now52.67%Needham
Gil Blum
 → $6ReiteratesBuy → BuyGet Alert
04/10/2024Buy Now52.67%Needham
Gil Blum
 → $6ReiteratesBuy → BuyGet Alert
03/28/2024Buy Now78.12%Cantor Fitzgerald
Kristen Kluska
 → $7ReiteratesOverweight → OverweightGet Alert
03/28/2024Buy Now52.67%Needham
Gil Blum
$5 → $6MaintainsBuyGet Alert
03/22/2024Buy Now78.12%Cantor Fitzgerald
Kristen Kluska
 → $7ReiteratesOverweight → OverweightGet Alert
09/08/2023Buy Now1.78%Cantor Fitzgerald
Kristen Kluska
 → $4ReiteratesOverweight → OverweightGet Alert
09/08/2023Buy Now27.23%Needham
Gil Blum
 → $5ReiteratesBuy → BuyGet Alert
08/23/2023Buy Now27.23%Needham
Gil Blum
 → $5ReiteratesBuy → BuyGet Alert
06/06/2023Buy Now27.23%Needham
Gil Blum
 → $5ReiteratesBuy → BuyGet Alert
05/26/2023Buy Now27.23%Needham
Gil Blum
 → $5ReiteratesBuy → BuyGet Alert
04/21/2023Buy Now27.23%Needham
Gil Blum
 → $5Reiterates → BuyGet Alert
03/30/2023Buy Now27.23%Needham
Gil Blum
 → $5Reiterates → BuyGet Alert
11/10/2022Buy Now1.78%SVB Leerink
Joseph Schwartz
$8 → $4MaintainsOutperformGet Alert
08/12/2022Buy Now1.78%Cantor Fitzgerald
Kristen Kluska
 → $4Initiates → OverweightGet Alert
06/06/2022Buy Now27.23%Needham
Gil Blum
$10 → $5MaintainsBuyGet Alert

FAQ

Q

What is the target price for Mereo BioPharma Group (MREO) stock?

A

The latest price target for Mereo BioPharma Group (NASDAQ:MREO) was reported by Leerink Partners on June 20, 2024. The analyst firm set a price target for $8.00 expecting MREO to rise to within 12 months (a possible 103.56% upside). 13 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Mereo BioPharma Group (MREO)?

A

The latest analyst rating for Mereo BioPharma Group (NASDAQ:MREO) was provided by Leerink Partners, and Mereo BioPharma Group maintained their outperform rating.

Q

When was the last upgrade for Mereo BioPharma Group (MREO)?

A

There is no last upgrade for Mereo BioPharma Group

Q

When was the last downgrade for Mereo BioPharma Group (MREO)?

A

There is no last downgrade for Mereo BioPharma Group.

Q

When is the next analyst rating going to be posted or updated for Mereo BioPharma Group (MREO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mereo BioPharma Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mereo BioPharma Group was filed on June 20, 2024 so you should expect the next rating to be made available sometime around June 20, 2025.

Q

Is the Analyst Rating Mereo BioPharma Group (MREO) correct?

A

While ratings are subjective and will change, the latest Mereo BioPharma Group (MREO) rating was a maintained with a price target of $6.00 to $8.00. The current price Mereo BioPharma Group (MREO) is trading at is $3.93, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch